Last reviewed · How we verify
Placebo for relugolix — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo for relugolix (Placebo for relugolix) — Myovant Sciences GmbH. A placebo control contains no active pharmaceutical ingredient and serves as a comparator in clinical trials to establish the efficacy of relugolix.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo for relugolix TARGET | Placebo for relugolix | Myovant Sciences GmbH | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo for relugolix CI watch — RSS
- Placebo for relugolix CI watch — Atom
- Placebo for relugolix CI watch — JSON
- Placebo for relugolix alone — RSS
Cite this brief
Drug Landscape (2026). Placebo for relugolix — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-for-relugolix. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing